期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
国产长春瑞滨联合顺铂治疗转移性乳腺癌的临床观察 被引量:5
1
作者 王燕 《临床肿瘤学杂志》 CAS 2003年第4期298-298,F003,共2页
目的 :观察国产长春瑞滨 (盖诺 )联合顺铂方案治疗转移性乳腺癌的临床疗效。方法 :运用盖诺 (2 5mg/m2 IVDd1,d8)加顺铂 (DDP 80mg/m2 IVd1)治疗转移性乳腺癌 2 6例。结果 :取得CR 3例 (11 5 %) ,PR 12例 (46 1%) ,总有效率RR(CR+PR)达... 目的 :观察国产长春瑞滨 (盖诺 )联合顺铂方案治疗转移性乳腺癌的临床疗效。方法 :运用盖诺 (2 5mg/m2 IVDd1,d8)加顺铂 (DDP 80mg/m2 IVd1)治疗转移性乳腺癌 2 6例。结果 :取得CR 3例 (11 5 %) ,PR 12例 (46 1%) ,总有效率RR(CR+PR)达 5 7 6 %。主要毒副作用为骨髓抑制 ,胃肠道反应和静脉炎。白细胞减少的发生率 10 0 %,其中Ⅲ~Ⅳ度达 5 7 7%。恶心、呕吐的发生率 92 3%,Ⅲ~Ⅳ度达 11 5 %。静脉炎的发生率 15 4 %。结论 :国产长春瑞滨联合顺铂对转移性乳腺癌疗效确切 ,且毒性可以耐受 ,可以作为对蒽环类药物治疗后复发 ,转移乳腺癌患者的二线治疗方案。 展开更多
关键词 春瑞滨 顺铂 联合治疗 转移性乳腺癌 临床观察 疗效 毒副作用
下载PDF
复脉膏外敷对大鼠长春瑞滨外渗性损伤的影响 被引量:5
2
作者 周留勇 单珍珠 +2 位作者 尤建良 张辰岑 龚时夏 《中药药理与临床》 CAS CSCD 北大核心 2014年第2期146-149,共4页
目的:通过复脉膏外敷对大鼠长春瑞滨外渗性损伤组织的病理观察,并研究其对外渗性损伤组织中VEGF、EGFR的影响,以探讨复脉膏外敷防治化疗性静脉炎的疗效及机制。方法:42只大鼠随机分为两组:复脉膏组、50%硫酸镁组,两组大鼠左侧损伤处分... 目的:通过复脉膏外敷对大鼠长春瑞滨外渗性损伤组织的病理观察,并研究其对外渗性损伤组织中VEGF、EGFR的影响,以探讨复脉膏外敷防治化疗性静脉炎的疗效及机制。方法:42只大鼠随机分为两组:复脉膏组、50%硫酸镁组,两组大鼠左侧损伤处分别予复脉膏外敷、50%硫酸镁湿敷;右侧予生理盐水外敷作为对照组。在损伤后第1、4、7、11、14、18天,分别随机取5只大鼠,测量外渗性损伤部位;并分别随机取3只大鼠,切除损伤部位的皮肤及皮下组织,以备观察。观察指标:皮损面积、病理观察、VEGF及EGFR的表达。结果:复脉膏(0.2g)外敷较硫酸镁湿敷及生理盐水外涂能明显减小各时间点的平均皮损面积。复脉膏组损伤皮肤早期炎症反应较硫酸镁组及对照组为轻,未见出血及血栓形成,后期可见损伤部位有充足的肉芽组织及新鳞状上皮生成。复脉膏(0.2g)外敷较硫酸镁湿敷及生理盐水外涂能明显刺激损伤组织中VEGF的阳性表达。复脉膏(0.2g)外敷较硫酸镁湿敷及生理盐水外涂能更早更强刺激损伤皮肤中EGFR的阳性表达。结论:复脉膏外敷于损伤皮肤后能上调VEGF的表达,促进EGFR的快速增加,进而促进损伤皮肤组织的愈合。 展开更多
关键词 复脉膏 春瑞滨 外渗性损伤 VEGF EGFR 化疗性静脉炎
原文传递
Effects of Pachyman in Combination with Vinorelbine and Cisplatin on Tumor Growth and the Expression of EGFR and K-ras in Mice with Lung Cancer 被引量:9
3
作者 Ke WEI Jia-Hao ZHOU +11 位作者 Yong-Chao CHEN Jia-Ming TIAN Meng-Jin SUN Xin-Wen DAI Bai-Hui LI Ling LI Fang-Liang ZHOU Yi NING Jue HU Qin XIANG Bo ZHANG Fang-Guo LU 《Digital Chinese Medicine》 2018年第4期310-315,共6页
Objective To examine the effects of pachyman in combination with vinorelbine and cisplatin on tumor growth and the expression of epidermal growth factor receptor(EGFR)and K-ras in a mouse model of lung cancer induced ... Objective To examine the effects of pachyman in combination with vinorelbine and cisplatin on tumor growth and the expression of epidermal growth factor receptor(EGFR)and K-ras in a mouse model of lung cancer induced using the human lung cancer cell line A549,and to investigate the molecular mechanisms underlying the antitumor effects of pachyman.Methods We recorded the size of the tumor xenografts in mice after treatment with pachyman monotherapy or pachymanin combination with vinorelbine and cisplatin.We performed immunohistochemical analysis to determine the levels of expression and distribution of EGFR and K-ras in lung cancer tissues.Real-time fluorescence quantitative PCR was used to determine the relative mRNA expression levels of EGFR and K-ras in lung cancer tissues.Results Vinorelbine and cisplatin significantly decreased the rate of growth of A549 xenografts,and pachyman increased the efficacy of vinorelbine and cisplatin.EGFR and K-ras were widely expressed in A549 xenografts.Vinorelbine and cisplatin could significantly decrease the expression,distribution and mRNA expression levels of EGFR and K-ras in tumor tissues.Pachyman monotherapy significantly decreased the distribution and the mRNA expression levels of EGFR in lung cancer tissues.In addition,pachyman in combination with vinorelbine and cisplatin markedly decreased the distribution and expression levels of EGFR in lung cancer tissues.However,pachyman monotherapy or combination therapy did not significantly decrease the mRNA expression levels of K-ras.Conclusion Thus,pachyman in combination with vinorelbine can significantly inhibit the growth of A549 xenografts,and pachyman can regulate the expression of the EGFR gene to increase the efficacy of vinorelbine and cisplatin in lung cancer and decrease the side effects associated with chemotherapy. 展开更多
关键词 Pachyman VINORELBINE CISPLATIN Lung cancer EGFR K-RAS
下载PDF
Development of targeted sunitinib plus vinorelbine liposomes modified with DSPE-PEG_(2000)-pemetrexed conjugate and the inhibitory effect toresistant breast cancer in vitro
4
作者 石继凤 居瑞军 +4 位作者 孙梦舸 李秀英 赵曜 曾凡 吕万良 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2014年第5期287-294,共8页
Multidrug resistance (MDR) of breast cancer is a major cause of failure in chemotherapy. In the present study, a distearoylphosphatidyl ethanolamine-polyethylene glycol-pemetrexed (DSPE-PEG2000-PMT) conjugate was ... Multidrug resistance (MDR) of breast cancer is a major cause of failure in chemotherapy. In the present study, a distearoylphosphatidyl ethanolamine-polyethylene glycol-pemetrexed (DSPE-PEG2000-PMT) conjugate was synthesized from DSPE-PEG2000-NH2 and pemetrexed, and targeted sunitinib plus vinorelbine liposomes were developed by modifying DSPE-PEG20o0-PMT onto the surface of liposomes to overcome the MDR of breast cancer. The synthesized DSPE-PEG2000-PMT was confirmed to be consistent with the target product by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The concentrations of sunitinib and vinorelbine were measured simultaneously by high performance liquid chromatography (HPLC). The analysis was performed on an ODS column at 30℃ at a wavelength of 215 nm with the mobile phase consisting of acetonitrile, 0.05 M KH2PO4 (pH 3.5) and triethylamine (35:65:0.3, v/v/v). The limits of detection for sunitinib and vinorelbine were 25 ng/mL and 5 ng/mL, respectively, and the limits of quantification for both drugs were 0.25μg/mL. Two drugs were linearly correlated in the range of 0.5-25.0 μg/mL. For varying types of liposomes, the encapsulation efficiencies were 〉90%; the particle sizes were approximately 90 nm, and zeta potentials were slightly negative. The inhibitory effects were evaluated in the resistant breast cancer MCF-7/Adr cells. The results revealed that targeted sunitinib plus vinorelbine liposomes exhibited the strongest inhibitory effect to the resistant MCF-7/Adr cells among the varying formulations. Targeted coumarin liposomes were used as a fluorescent probe to evaluate the targeting effect to resistant breast cancer MCF-7/Adr cells. The results demonstrated that the targeted coumarin liposomes displayed the highest cellular uptake compared to non-targeted formulations. In conclusion, the targeted sunitinib plus vinorelbine liposomes represented a novel type of nano-formulations, which could accumulate in the resistant breast cancer cells, thereby inhibiting proliferation of the resistant cancer cells. Accordingly, the targeted sunitinib plus vinorelbine liposomes may provide a new strategy for circumventing the drug resistance in the resistant breast cancer. 展开更多
关键词 DSPE-PEG2000-pemetrexed SUNITINIB VINORELBINE Targeted liposomes Resistant breast cancer
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部